Brokerages expect Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Rating) to report ($0.56) earnings per share for the current fiscal quarter, according to Zacks. Four analysts have made earnings estimates for Seres Therapeutics. The highest EPS estimate is ($0.48) and the lowest is ($0.61). Seres Therapeutics posted earnings of ($0.39) per share in the same quarter last year, which would indicate a negative growth rate of 43.6% year over year. The company is expected to release its next earnings report on Monday, January 1.
On average, analysts expect Seres Therapeutics to report annual earnings of $2.05 per share for the current fiscal year, with EPS estimates ranging from $2.59 to $1.47. For next year, analysts expect the company to post earnings of ($1.16) per share, with EPS estimates ranging from ($2.86) to $0.29. Zacks EPS averages are an average based on a survey of research companies that provide coverage for Seres Therapeutics.
Seres Therapeutics (NASDAQ:MCRB – Get Rating) last reported results on Tuesday, March 1. The biotech company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.10). The company posted revenue of $7.22 million for the quarter, versus $19.48 million expected by analysts. Seres Therapeutics had a negative net margin of 45.25% and a negative return on equity of 47.52%. In the same quarter a year earlier, the company posted ($0.18) earnings per share.
Several brokerages have recently published reports on the MCRB. StockNews.com began covering Seres Therapeutics shares in a research report on Thursday, March 31. They have placed a “holding” rating on the stock. Zacks Investment Research upgraded shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a Thursday, March 3, research report. Two equity research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned the stock a buy rating. According to MarketBeat, Seres Therapeutics currently has an average rating of “Hold” and a consensus price target of $20.83.
Shares of the NASDAQ MCRB traded down $0.50 in midday trading on Monday, hitting $6.08. 553,459 shares of the company were traded, compared to its average volume of 645,331. The company’s 50-day moving average is $7.37 and its two-hundred-day moving average is $7.75. The company has a quick ratio of 3.69, a current ratio of 3.69 and a leverage ratio of 0.19. Seres Therapeutics has a 1-year minimum of $5.41 and a 1-year maximum of $25.06.
A number of large investors have recently changed their stock holdings. Two Sigma Investments LP increased its stake in Seres Therapeutics by 527.8% in Q3. Two Sigma Investments LP now owns 999,416 shares of the biotech company worth $6,956,000 after acquiring an additional 840,214 shares last quarter. HAP Trading LLC bought a new position in Seres Therapeutics in Q3 worth approximately $279,000. Janney Montgomery Scott LLC bought a new position in Seres Therapeutics in Q3 worth approximately $186,000. Cubist Systematic Strategies LLC increased its stake in Seres Therapeutics by 1,049.1% in Q3. Cubist Systematic Strategies LLC now owns 318,190 shares of the biotech company worth $2,215,000 after acquiring an additional 290,499 shares last quarter. Finally, Hudson Bay Capital Management LP bought a new position in Seres Therapeutics in Q3 worth approximately $3,271,000. Institutional investors hold 80.53% of the company’s shares.
About Seres Therapeutics (Get a rating)
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in the development of bacterial consortia designed to functionally interact with host cells and tissues to treat disease. The Company’s lead product candidate is SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of Clostridium difficile infection (CDI).
Get a Free Copy of Zacks Research Report on Seres Therapeutics (MCRB)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for Seres Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Seres Therapeutics and related companies with MarketBeat.com’s free daily email newsletter.